M L V and Co L L C [Member]
MLV & Co. LLC
Represents details pertaining to MLV and Co. LLC, with whom the entity entered into an at-the-market sales agreement.
Azimuth Opportunity Ltd [Member]
Azimuth Opportunity Ltd.
Represents details pertaining to Azimuth Opportunity Ltd., with whom the entity entered into a common stock purchase agreement.
Computers and Software [Member]
Computers and software
Long-lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and purchased software applications.
Corporate Debt Securities Due within Three Months [Member]
Corporate debt securities due within 3 months of date of purchase
Debt securities due within three months of date of purchase issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.
Stock Plan 2006 [Member]
2006 Stock Plan
Represents the 2006 Stock Plan of the entity.
Hoffman La Roche [Member]
Roche
Represents information pertaining to Hoffman-La Roche.
Award Type [Axis]
Co development Agreement [Member]
Co-Development Agreement
Represents the co-development agreement of the entity.
General Electric Capital Corporation Term Loan [Member]
GECC Term Loan
Represents the General Electric Capital Corporation Term Loan in which General Electric Capital Corporation is the lender of the debt.
Oxford Finance Corporation Term Loan [Member]
Oxford Term Loan
Represents the Oxford Finance Corporation Term Loan in which Oxford Finance Corporation is the lender of the debt.
Stock Plan 2001 [Member]
2001 Stock Plan
Represents the 2001 Stock Plan of the entity.
Amendment Description
Cash and Money Market Funds [Member]
Cash and money market funds
Currency on hand as well as demand deposits with banks or financial institutions. It includes other kinds of accounts that have the general characteristics of demand deposits and a fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, bankers acceptances, repurchase agreements, government securities, certificates of deposit and other highly liquid securities.
Amendment Flag
Document and Entity Information
Accrued Contract Research Costs
Accrued contract research costs
The carrying value as of the balance sheet date of obligations incurred and payable relating to service fees paid to contract manufacturers in connection with the production of clinical drug supplies and to contract research organizations in connection with preclinical studies and clinical trials. Used to reflect the current portion of liabilities (due within one year or within the normal operating cycle if longer).
Accrued Liabilities Current Excluding Accrued Contract Research Costs
Other accrued liabilities
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Excludes accrued contract research costs. (Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Other accrued liabilities
Collaboration Revenues [Abstract]
Collaboration revenues:
License and Milestone Revenues
License and milestone revenue
Revenues earned by the entity under collaborative research and development agreements for nonrefundable, up-front license fees and milestone payments, excluding cost sharing reimbursements of research and development costs.
Collaborative Revenues
The aggregate revenue earned under collaborative research and development agreements.
Total collaboration revenues
Cost Sharing Reimbursements
Cost sharing reimbursements, net
Reimbursements earned by the entity for costs incurred under collaborative research and development agreements are recognized as cost sharing revenue in the period in which the related research and development costs are incurred. Reimbursements by the entity for agreed-upon costs incurred by partners under collaborative research and development agreements are recognized as a reduction in cost sharing revenue in the period in which the related research and development costs are incurred.
Arrangements and Non-arrangement Transactions [Domain]
Total revenues
Total Revenues
Total aggregate revenue earned under collaborative research and development agreements and grants.
Increase (Decrease) Accrued Contract and Research Costs
Accrued contract research costs
The increase (decrease) during the reporting period in accrued contract research costs.
The increase (decrease) during the reporting period in collaboration payable.
Collaboration payable
Increase (Decrease) in Collaboration Payable
Collaboration payable
Proceeds from the issuance of common stock to related parties
Proceeds from Issuance of Common Stock to Related Parties
Represents the proceeds from the issuance of common stock to related parties.
Other Accrued Liabilities Disclosure [Text Block]
Other Accrued Liabilities
The disclosure for accrued liabilities at the end of the reporting period, excluding accrued contract research costs.
License and Development Agreements
Schedule Of Share Based Compensation Expense Allocation of Compensation Costs and Recognized Period Costs [Table Text Block]
Schedule of stock-based compensation expense
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the income statement for the period. This may include the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits. It includes the reporting line for the costs expensed.
Schedule of Other Accrued Liabilities [Table Text Block]
Schedule of other accrued liabilities
Tabular disclosure of the components of other accrued liabilities which excludes accrued contract research costs.
Grant Revenue [Abstract]
Grant Revenue
Current Fiscal Year End Date
Amount of Grant Awarded
Amount of grant awarded for development of STA-9584 in advanced prostate cancer
The amount of the grant awarded from a governmental agency.
Period of Grant Received
Period of grant received
Represents the period of the grant.
Share based Compensation Arrangement by Share based Payment Award Fair Value Assumptions Forfeiture Rate
Forfeiture rate (as a percent)
The forfeiture rate assumption that is used in valuing an option on its own shares.
Maturity Period from Date of Purchase to Classify Investment as Cash and Cash Equivalents
Represents the maturity period from date of purchase to classify an investment as cash and cash equivalents.
Maturity period from date of purchase to classify an investment as cash and cash equivalents
Maturity Period from Date of Purchase to Classify Investment as Marketable Securities
Represents the maturity period from date of purchase to classify an investment as marketable securities.
Maturity period from date of purchase to classify an investment as marketable securities
Cash and Cash Equivalents and Available for sale Securities, Gross Unrealized Gains
Cash, cash equivalents and marketable securities, unrealized gains
This item represents the gross unrealized gains for cash and cash equivalents securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities.
Cash and Cash Equivalents and Available for sale Securities, Gross Unrealized Losses
Cash, cash equivalents and marketable securities, unrealized losses
This item represents the gross unrealized losses for cash and cash equivalents securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities.
Public Offering [Abstract]
Public Offering
Proceeds from Issuance or Sale of Equity, Gross
Gross proceeds from the sale of common stock
Represents the cash inflow from the sale of common stock before deducting underwriters' discounts, fees and commissions, and other offering expenses.
Stock Issued During Period Shares to Directors
Issuance of common shares to directors
Represents the number of shares sold to the directors of the entity in the public offering.
Expected Proceeds from Issuance or Sale of Equity
Expected proceeds from sale of common stock
Represents the expected cash inflow from the issuance of common stock by the entity.
Document Period End Date
Expected Stock Issuance During Period Shares
Expected sale of common stock (in shares)
Represents the expected number of new stock issued during the period.
Percentage of Gross Proceeds Payable as Commission
Percentage of gross proceeds payable as commission
Represents the percentage of gross proceeds payable as commission during the period.
Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Authorized before Annual Increase
Number of shares reserved for issuance before annual increase
Represents the number of shares reserved for issuance under the equity-based compensation plan before the issuance of the annual evergreen increase in the number of shares authorized for issuance.
Share based Compensation Arrangement by Share based Payment Award, Annual Increase in Number of Shares Authorized
Annual increase in number of shares reserved for issuance
Represents the annual increase in the maximum number of shares (or other type of equity) that was initially approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan.
Share based Compensation Arrangement by Share based Payment Award, Percentage on Outstanding Common Stock for Computation of Annual Increase in Number of Shares Reserved for Issuance
Percentage of outstanding shares of common stock used to compute annual increase in number of shares reserved for issuance
Represents the percentage of outstanding shares of common stock used to compute the annual increase in the number of shares reserved for issuance.
Share based Compensation Arrangement by Share based Payment Award, Expiration Term
Expiration period
The period of time, from the grant date until the time at which the share-based [option] award expires.
Share based Compensation Arrangement by Share based Payment Award, Options Outstanding Weighted Average Exercise Price [Abstract]
Weighted average exercise price
Collaborative Arrangement, Upfront License Fee Received
Upfront license fee received
Represents the non-refundable upfront license payment received.
Collaborative Arrangement, Initial Term for Research
Initial term for research
Represents the initial term for research under collaborative arrangements.
Entity [Domain]
Collaborative Arrangement, Research and Development Support Received
Amount received related to research and development support
Represents the amount received in research and development support.
Collaborative Arrangement, Non Refundable Upfront License Fee Accelerated Recognition
Accelerated recognition of remaining deferred revenue from upfront payment
Represents the accelerated recognition of remaining deferred revenue from upfront payment during the period under the collaborative agreement.
Collaborative Arrangement, License Revenue Recognized
License revenue recognized
Represents the license revenue recognized during the period under the collaborative agreement.
Number of Clinical Research Organizations
Number of clinical research organizations
Represents the number of clinical research organizations with which the entity entered into an agreement for conducting certain company-sponsored clinical trials.
Debt Instrument, Number of Equal Monthly Payments of Principal Plus Accrued Interest
Number of equal monthly payments of principal plus accrued interest
Represents the number of equal monthly payments of principal plus accrued interest made by the entity.
Debt Instrument, Exit Fee Payable at End of Term
Exit fee to be paid
Represents the obligation to pay exit fee at the time of final payment of the outstanding principal balance.
Debt Instrument, Covenant Equipment Financing Allowed without any Restriction
Amount of equipment financing allowed under covenants without any restriction
Represents the amount of equipment financing allowed without any restrictive covenants.
Debt Instrument, Covenant Debt Assumption from Acquisitions Requiring Prior Written Consent
Amount of debt assumption from acquisitions requiring prior written consent under covenants
Represents the amount of debt assumption from acquisitions requiring prior written consent.
Stock Issued During Period, Value, Related Party
Issuance of common shares to related parties
Equity impact of the value of stock issued during the period to related party by the reporting entity.
Proceeds from the sale of common stock to related parties
Stock Issued During Period, Shares, Related Party
Issuance of common shares to a related party, net (in shares)
Number of shares issued to related party during the reporting period.
Collaborative Development, Commercialization and License Agreement with GSK
Collaborative Arrangement Second Disclosure [Text Block]
Collaborative Development, Commercialization and License Agreement with GSK
The entire disclosure for second collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations there under; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
Available-for-sale Securities, Gross Unrealized Gains
Marketable securities, Unrealized gains
Summary of Significant Accounting Policies
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Filer Category
Entity Public Float
Entity Registrant Name
Entity Central Index Key
Entity Common Stock, Shares Outstanding
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Other Accrued Liabilities
Document Fiscal Year Focus
Document Fiscal Period Focus
Legal Entity [Axis]
Document Type
Accounts Payable, Current
Accounts payable
Professional fees
Accrued Professional Fees, Current
Accumulated other comprehensive income (loss)
Accumulated Other Comprehensive Income (Loss) [Member]
Less accumulated depreciation and amortization
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive income
Additional Paid in Capital, Common Stock
Additional paid-in-capital
Additional paid-in Capital
Additional Paid-in Capital [Member]
Compensation expense related to stock options for services
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Allocated Share-based Compensation Expense
Total stock-based compensation expense
Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Basic and Diluted Loss Per Common Share
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities, Name [Domain]
Antidilutive Securities [Axis]
Assets, Current [Abstract]
Current assets:
Assets [Abstract]
Assets
Assets, Current
Total current assets
Assets
Total assets
Marketable securities
Available-for-sale Securities, Fair Value Disclosure
Available-for-sale Securities, Current
Marketable securities
Available-for-sale Securities, Gross Unrealized Losses
Marketable securities, Unrealized losses
Available-for-sale Securities, Amortized Cost Basis
Marketable securities, Cost
Acquisition of equipment under capital leases
Capital Expenditures Incurred but Not yet Paid
GECC existing equipment leases
Capital Lease Obligations [Member]
Capital Lease Obligations, Current
Capital lease obligations
Capital Lease Obligations, Noncurrent
Capital lease obligations
Cost
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents
Cash, Cash Equivalents and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities [Text Block]
Cash, Cash Equivalents and Marketable Securities
Cash and Cash Equivalents, Fair Value Disclosure
Cash and cash equivalents
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Supplemental disclosure of noncash operating, investing and financing activities:
Total cash, cash equivalents and marketable securities
Cash, Cash Equivalents, and Short-term Investments
Stockholders' Equity
Class of Stock [Line Items]
License and Development Agreements
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangement Disclosure [Text Block]
License and Development Agreements
Roche Agreement
Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]
Collaborative Arrangements and Non-collaborative Arrangements [Axis]
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Commitments and Contingencies.
Commitments and contingencies (Note 11)
Commitments and Contingencies
Common stock
Common Stock [Member]
Common Stock, Shares, Outstanding
Common stock, shares outstanding
Common Stock, Value, Issued
Common stock, par value $0.0001 per share Authorized: 100,000,000 shares at June 30, 2012 and December 31, 2011; 57,812,955 and 49,539,808 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively
Common Stock, Shares, Issued
Common stock, shares issued
Balance (in shares)
Balance (in shares)
Common Stock, Par or Stated Value Per Share
Common stock, par value (in dollars per share)
Common Stock, Shares Authorized
Common stock, Authorized shares
Retirement Plan
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive loss
Comprehensive Income, Policy [Policy Text Block]
Comprehensive Loss
Comprehensive income (loss)
Comprehensive Income [Member]
Consolidation, Policy [Policy Text Block]
Principles of Consolidation
Corporate Debt Securities [Member]
Corporate debt securities due within 1 year of date of purchase
Operating expenses:
Costs and Expenses [Abstract]
Term Loans
Debt Instrument [Line Items]
Schedule of Long-term Debt Instruments [Table]
Debt Disclosure [Text Block]
Term Loans
Term Loans
Legal fees and expenses paid
Debt Issuance Cost
Principal amount of debt issued
Debt Instrument, Increase, Additional Borrowings
Annual interest rate on term loan (as a percent)
Debt Instrument, Interest Rate, Stated Percentage
Deferred Revenue, Noncurrent
Deferred collaboration revenue, net of current portion
Deferred collaboration revenue
Deferred Revenue, Current
Depreciation and amortization
Depreciation, Depletion and Amortization
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Stock-Based Compensation
Stock-Based Compensation
Earnings Per Share, Diluted
Diluted (in dollars per share)
Earnings Per Share, Basic
Basic (in dollars per share)
Earnings Per Share, Basic and Diluted
Basic and diluted net loss per common share (in dollars per share)
Earnings Per Share, Policy [Policy Text Block]
Basic and Diluted Loss Per Common Share
Earnings Per Share [Abstract]
Net loss per common share:
Compensation and benefits
Employee-related Liabilities, Current
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition
Weighted average remaining period
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized
Unrecognized stock compensation expense
Laboratory equipment
Equipment [Member]
Equity Component [Domain]
Fair Value
Estimate of Fair Value, Fair Value Disclosure [Member]
Fair Value, Hierarchy [Axis]
Fair Value, Measurements, Fair Value Hierarchy [Domain]
Fair Value Measurements
Fair Value Disclosures [Text Block]
Fair Value Measurements
Fair Value of Financial Instruments, Policy [Policy Text Block]
Fair Value of Financial Instruments
Fair Value, Disclosure Item Amounts [Domain]
Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]
Level 1
Fair Value, Inputs, Level 1 [Member]
Level 2
Fair Value, Inputs, Level 2 [Member]
Furniture and fixtures
Furniture and Fixtures [Member]
General and Administrative Expense
General and administrative
General and Administrative Expense [Member]
General and administrative
Condensed Consolidated Statements of Operations
Income Taxes
Income Tax Disclosure [Text Block]
Income Taxes
Accounts payable
Increase (Decrease) in Accounts Payable, Trade
Increase (Decrease) in Deferred Revenue
Deferred collaboration revenue
Increase (Decrease) in Other Noncurrent Assets
Other assets
Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities:
Increase (Decrease) in Prepaid Expense and Other Assets
Prepaid expenses and other current assets
Increase (Decrease) in Other Accrued Liabilities
Other accrued liabilities
Increase (Decrease) in Restricted Cash for Operating Activities
Restricted cash
Increase (Decrease) in Receivables
Collaboration receivable
Increase (Decrease) in Stockholders' Equity
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest Income (Expense), Nonoperating, Net
Interest expense, net
Interest expense recognized
Interest Expense, Debt
Interest Paid
Cash paid for interest
Long-term Debt, Type [Domain]
Long-term Debt, Type [Axis]
Leasehold improvements
Leasehold Improvements [Member]
Liabilities, Current
Total current liabilities
Liabilities, Noncurrent
Total long-term liabilities
Liabilities, Current [Abstract]
Current liabilities:
Liabilities
Total liabilities
Liabilities, Noncurrent [Abstract]
Long-term liabilities:
Liabilities and Equity [Abstract]
Liabilities and Stockholders' Equity
Liabilities and Equity
Total liabilities and stockholders' equity
Origination and amendment fees paid
Loan Processing Fee
2012
Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year
2014
Long-term Debt, Maturities, Repayments of Principal in Year Three
2013
Long-term Debt, Maturities, Repayments of Principal in Year Two
Marketable Securities, Policy [Policy Text Block]
Marketable Securities
Future principal payments under the GECC and Oxford Term Loans
Maturities of Long-term Debt [Abstract]
Maximum [Member]
Maximum
Minimum [Member]
Minimum
Nature of Operations [Text Block]
Nature of Business
Cash flows from financing activities:
Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]
Net cash used in operating activities
Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Cash flows from operating activities:
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net decrease in cash and cash equivalents
Net Cash Provided by (Used in) Continuing Operations
Net cash used in investing activities
Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Net loss
Net loss
Net Income (Loss) Available to Common Stockholders, Basic
Net cash provided by financing activities
Net Cash Provided by (Used in) Financing Activities, Continuing Operations
Cash flows from investing activities:
Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]
Number of operating segments
Number of Operating Segments
Operating Expenses
Total operating expenses
Operating Income (Loss)
Loss from operations
Nature of Business
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Other Assets, Noncurrent
Other assets
Other
Other Liabilities, Current
Other Nonoperating Income (Expense)
Other (expense) income, net
Other Nonoperating Income (Expense) [Abstract]
Other (expense) income:
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Other comprehensive (loss) income:
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Total other comprehensive (loss) income
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent
Unrealized gain (loss) on marketable securities
Unrealized (loss) gain on available-for-sale securities
Other Accrued Liabilities
Payments to Acquire Property, Plant, and Equipment
Purchases of property and equipment
Payments to Acquire Available-for-sale Securities
Purchases of marketable securities
Retirement Plan
Pension and Other Postretirement Benefits Disclosure [Text Block]
Plan Name [Domain]
Plan Name [Axis]
Preferred Stock, Value, Issued
Preferred stock, par value $0.0001 per share Authorized: 5,000,000 shares at June 30, 2012 and December 31, 2011; no shares issued and outstanding at June 30, 2012 and December 31, 2011
Preferred Stock, Shares Authorized
Preferred stock, Authorized shares
Preferred Stock, Shares Issued
Preferred stock, shares issued
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value (in dollars per share)
Preferred Stock, Shares Outstanding
Preferred stock, shares outstanding
Prepaid Expense and Other Assets, Current
Prepaid expenses and other current assets
Proceeds from Issuance of Secured Debt
Proceeds from term loans
Net offering proceeds after deducting underwriters' discounts, fees and commissions, and other offering expenses payable
Proceeds from Issuance or Sale of Equity
Net proceeds to the Company after deducting estimated offering expenses payable
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities
Maturities of marketable securities
Property, Plant and Equipment, Type [Domain]
Property and Equipment
Property and equipment, net
Property, Plant and Equipment, Net
Property and equipment, net
Property and Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross
Property, Plant and Equipment, Gross
Schedule of property and equipment
Property, Plant and Equipment [Table Text Block]
Property, Plant and Equipment, Type [Axis]
Property, Plant and Equipment Disclosure [Text Block]
Property and Equipment
Quarterly Financial Data (unaudited)
Quarterly Financial Information [Text Block]
Quarterly Financial Data (unaudited)
Range [Axis]
Range [Domain]
Receivables, Long-term Contracts or Programs
Collaboration receivable
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Related Party Transactions
Repayments of Long-term Capital Lease Obligations
Payment of capital lease obligations
Repayment of remaining principal outstanding under existing equipment leases
Payment of term loans
Repayments of Secured Debt
Research and Development Expense (Excluding Acquired in Process Cost)
Research and development
Research and Development Expense [Member]
Research and development
Unvested restricted common stock
Restricted Stock [Member]
Restricted stock awards
Restricted stock
Restructuring
Restructuring and Related Activities Disclosure [Text Block]
Restructuring Charges
Restructuring
Restructuring
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Accumulated deficit
Retained Earnings [Member]
Grant revenues
Revenue from Grants
Revenue Recognition, Policy [Policy Text Block]
Revenue Recognition
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term
Expected life in years
Revenue, Net [Abstract]
Revenues:
Scenario, Unspecified [Domain]
Schedule of unrecognized stock-based compensation expense
Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]
Schedule of Investments [Table]
Summary unvested restricted shares
Schedule of Nonvested Share Activity [Table Text Block]
Summary of stock option activity
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
Schedule of weighted average assumptions used to estimate fair value of each employee stock option award
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Schedule of future principal payments under the GECC and Oxford Term Loans
Schedule of Maturities of Long-term Debt [Table Text Block]
Summarizes outstanding securities not included in computation of diluted net loss per common share as their inclusion would be anti-dilutive
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Summary of cash, cash equivalents and available-for-sale marketable securities
Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]
Schedule of Investments [Line Items]
Cash, Cash Equivalents and Marketable Securities
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Property, Plant and Equipment [Table]
Schedule of Stock by Class [Table]
Secured Long-term Debt, Noncurrent
Term loans, net of current portion
Secured Debt, Current
Current portion of term loans
Total future principal payments
Secured Debt
Segment Reporting
Segment Reporting [Abstract]
Segment Reporting, Policy [Policy Text Block]
Segment Reporting
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Weighted average grant date fair value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares
Share-based Compensation
Stock-based compensation expense
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Options cancelled (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Outstanding at the beginning of the period (in dollars per share)
Outstanding at the end of the period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period
Vesting period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Options granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation
Stock-based compensation expense
Unrecognized stock-based compensation expense
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Outstanding at the beginning of the period (in shares)
Outstanding at the end of the period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Vested (in shares)
Stock-Based Compensation
Share-based Compensation [Abstract]
Selling price per share (in dollars per share)
Share Price
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Options granted (in dollars per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Options exercised (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Risk-free interest rate (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Volatility (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Exercisable at the end of the period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Expected dividend yield (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Vested (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value of options (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Additional disclosures
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Exercisable at the end of the period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant
Shares available for future issuance
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Shares
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized
Shares reserved for issuance
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Weighted average assumptions used to estimate fair value of each employee stock option award
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)
Outstanding at the end of the period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Outstanding at the beginning of the period (in shares)
Outstanding at the end of the period (in shares)
Award Type [Domain]
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Stock-Based Compensation
Statement [Table]
Scenario [Axis]
Statement [Line Items]
Statement
Consolidated Statements of Stockholders' Equity and Comprehensive Income (Loss)
Condensed Consolidated Statements of Cash Flows
Equity Components [Axis]
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Comprehensive Loss
Stock Issued During Period, Shares, Period Increase (Decrease)
Common stock options
Stock Options [Member]
Stock option
Employee stock options
Issuance of restricted common shares (in shares)
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Forfeitures of restricted common shares (in shares)
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited
Exercise of stock options
Stock Issued During Period, Value, Stock Options Exercised
Issuance of common shares in equity offering, excluding to related parties
Stock Issued During Period, Value, New Issues
Number of shares sold by the entity
Stock Issued During Period, Shares, New Issues
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Exercise of stock options (in shares)
Options exercised (in shares)
Stockholders' equity:
Stockholders' Equity Attributable to Parent [Abstract]
Total stockholders' equity
Stockholders' Equity Attributable to Parent
Balance
Balance
Stockholders' Equity
Stockholders' Equity Note Disclosure [Text Block]
Stockholders' Equity
Stockholders' Equity, Period Increase (Decrease)
Subsequent Events [Text Block]
Subsequent Event-Registered Direct Offering
Subsequent Event-Registered Direct Offering
Supplemental Cash Flow Information [Abstract]
Supplemental disclosure of cash flow information:
Type of Arrangement and Non-arrangement Transactions [Axis]
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Weighted-average common shares outstanding:
Basic and diluted weighted average number of common shares outstanding (in shares)
Weighted Average Number of Shares Outstanding, Basic and Diluted
Other Comprehensive Income Unrealized Holding Loss on Securities Arising During Period Net of Tax
Unrealized loss on available-for-sale securities
Net of tax amount of unrealized holding loss before reclassification adjustments and transfers on available-for-sale securities.
Unrealized gain on available-for-sale securities
Other Comprehensive Income Unrealized Holding Gain on Securities Arising During Period Net of Tax
Net of tax amount of unrealized holding gain before reclassification adjustments and transfers on available-for-sale securities.
Investment Type [Axis]
Investment Type Categorization [Domain]
Aggregate Number Of Shares Sold
Represents the aggregate number of shares sold by the entity.
Aggregate number of shares sold by the entity
Options cancelled (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Interest Expense Recognized for Debt Financing Costs
Origination, exit and transaction fees and expenses recognized in interest expense
Amount of expense included in interest expense to issue debt and obtain financing associated with the related debt instruments.
Cash and Cash Equivalents [Axis]
Major Types of Debt and Equity Securities [Axis]
Major Types of Debt and Equity Securities [Domain]
Cash and Cash Equivalents [Domain]
US Government Sponsored Enterprises and Corporate Debt Securities [Member]
Government-sponsored entities and corporate debt securities due within 3 months of date of purchase
Represents the debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Includes debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.
Subsequent Event
Subsequent Event [Member]
Registered Direct Offering
Issuance of Equity [Member]
Subsequent Event-Registered Direct Offering
Subsequent Event [Line Items]
Purchase price of shares sold by the Company (in dollars per share)
Equity Issuance, Per Share Amount
Financing [Axis]
Subsequent Event Type [Axis]
Financing [Domain]
Subsequent Event Type [Domain]
Subsequent Event [Table]
Reclassification in the Preparation of Financial Statements
Reclassification, Policy [Policy Text Block]
Proceeds from issuances of common stock
Prior Period Reclassification Adjustment
Proceeds from the issuance of common stock, excluding to related parties, net of transaction costs
Proceeds from Issuance of Common Stock
Proceeds from Issuance of Common Stock [Member]
Represents the cash inflow from the issuance of common stock, excluding issuances to related parties.
Proceeds from issuances of common stock
Proceeds from Issuance of Common Stock to Related Parties [Member]
Represents the cash inflow from the issuance of common stock to related parties.
Proceeds from the issuance of common stock to related parties
Prior Period Reclassification
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Adjustments for Error Corrections [Axis]
Adjustments for Error Correction [Domain]
Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]